[1] Jiang JF,Lao YC,Yuan BH,et al.Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges. Oncotarget,2017,8:33911-33921.
[2] Bosch FX,Rihes J,Diaz M,et al.Primary liver cancer:worldwide incidence and trends. Gastroenterology,2004,127:S5216.
[3] Lai EC,Lau WY. The continuing challenge of hepatic cancer in Asia.Surgeon 2005,3:210,215.
[4] 叶昶,程帆,祝存海,等. 基质金属蛋白酶-9和脆性组氨酸三联体基因在人类膀胱移行细胞癌中的表达及其意义.中华实验外科杂志,2013,30:1756-1757.
[5] Tsao I,Atramentova LA. Genetic and epigenetic changes of FHIT gene in patients with esophageal cancer. Tsitol Genet,2009,43:40-44.
[6] Bianchi F,Sasso M,Turdo et al. FHIT nuclear import following EGF stimulation sustains proliferation of breast cancer cells. J Cell Physiol,2015,230:2661-2670.
[7] Lin HY,Hung SK,Lee MS,et al. DNA methylome analysis identifies epigenetic silencing of FHIT as a determining factor for radiosensitivity in oral cancer:an outcome-predicting and treatment-implicating study. Oncotarget,2015,6:915-934.
[8] Haroun RA,Zakhary NI,Mohamed MR,et al. Assessment of the prognostic value of methylation status and expression levels of FHIT,GSTP1 and P16 in non-small cell lung cancer in Egyptian patients. Asian Pac J Cancer Prev,2014,15:4281-4287.
[9] 张燕子,曾祥毅,邹细红,等. FHIT和P16蛋白在非小细胞肺癌中的表达及意义. 中国现代医生,2013,51:147-148,15.
[10] Zhang C,Ye L,Guan S,et al. Autoantibodies against P16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer. Tumour Biol,2014,35:2047-2051. .
[11] Wani HA,Beigh MA,Amin S,et al. Methylation profile of promoter region of P16 gene in colorectal cancer patients of Kashmir valley. J Biol Regul Homeost Agents,2013,27:297-307.
[12] Powell WC,Knox JD,Navre M,et al. Expression of meta-lloproteinase mat rilysin in DU2145 cells increases the irinvasive potential in severe combined muno deficient mice. Cancer Res,1993,53:417.
[13] 蒋扬富,杨治华,胡敬群,等.血管内皮生长因子和基质金属蛋白酶-9在原发性肝癌中的表达及其临床意义.癌症,2000,19:17-19,33. |
